Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?

CONCLUSIONS: The results of this study suggest that the dose received by the region close to the PTV has a significant impact on the risk of distant metastases in stage I NSCLC patients treated with SBRT. If these results are independently confirmed, caution should be taken, particularly when a treatment plan results in a steep dose gradient extending outwards from the PTV.
PMID: 29801721 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - May 22, 2018 Category: Radiology Authors: Diamant A, Chatterjee A, Faria S, Naqa IE, Bahig H, Filion E, Robinson C, Al-Halabi H, Seuntjens J Tags: Radiother Oncol Source Type: research